Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma

Oncogene

Volumn 27, Issue 57, 2008, Pages 7162-7170

  Ohtani, Y ^a   Harada, T ^a   Funasaka, Y ^a   Nakao, K ^b   Takahara, C ^a   Abdel Daim, M ^a   Sakai, N ^c   Saito, N ^d   Nishigori, C ^a   Aiba, A ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY   (Japan)

Author keywords

Melanoma; mGluR1; Tetracycline; Transgenic

Indexed keywords

METABOTROPIC RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RILUZOLE; TETRACYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVATION; GENE FREQUENCY; GENE MUTATION; IN VIVO STUDY; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION; GENES, RAS; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, METABOTROPIC GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

MUS; MUS MUSCULUS;

EID: 57349145304     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.329     Document Type: Article

References (30)

1. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S. (1994a). Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 79: 365-375.
2. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K et al. (1994b). Deficient cerebellar long-termdepressio n and impaired motor learning in mGluR1 mutant mice. Cell 79: 377-388.
3. Chen J, Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE et al. (1998). Transgenic animals with inducible, targeted gene expression in brain. Mol Pharmacol 54: 495-503.
4. Chen S, Zhu H, Wetzel WJ, Philbert MA. (1996). Spontaneous melanocytosis in transgenic mice. J Invest Dermatol 106: 1145-1151.
5. Chin L, TamA, Pomerantz J, Wong M, Holash J, Bardeesy N et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
6. Chung JH, Whiteley M, Felsenfeld G. (1993). A 50 element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74: 505-514.
7. Conn PJ, Pin JP. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
8. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F et al. (1994). Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 372: 237-243.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 27: 949-954.
10. Gossen M, Bujard H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551.
11. Handerson T, Pawelek JM. (2003). β1,6-branced oligosaccharides and coarse vesicles: a common, pervasive phenotype in melanoma and other human cancers. Cancer Res 63: 5363-5369.
12. Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff Jr CL et al. (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279: 33168-33176.
13. KarimF, Wang CC, Gereau IV RW. (2001). Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 21: 3771-3779.
14. Marin YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M et al. (2006). Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 18: 1279-1286.
15. Marin YE, Namkoong J, Shin SS, Raines J, Degenhardt K, White E et al. (2005). Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology 49: 70-79.
16. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. (1991). Sequence and expression of a metabotropic glutamate receptor. Nature 349: 760-765.
17. E600 in benign and malignant human tumours. Oncogene 27: 877-895.
18. Nakanishi S. (1992). Molecular diversity of glutamate receptors and implications for brain function. Science 258: 597-603.
19. Nakanishi S. (1994). Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 13: 1031-1037.
20. Nambiar S, Mirmohammadsadegh A, Doroudi R, Gustrau A, Marini A, Roeder G et al. (2005). Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol 141: 165-173.
21. Namkoong J, Shin SS, Lee HJ, Marin YE, Wall BA, Goydos JS et al. (2007). Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67: 2298-2305.
22. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino J, Koganti A et al. (2003). Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nature Genet 4: 108-112.
23. Rzeski W, Turski L, Ikonomidou C. (2001). Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 6372-6377.
24. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759.
25. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
26. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE et al. (2005). NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102: 15605-15610.
27. Thandi S, Blank JL, Challiss RA. (2002). Group I metabotropic glutamate receptors, mGluR1a and mGluR5 couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signaling pathways. J Neurochem 83: 1139-1153.
28. Thomas NE. (2006). BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16: 97-103.
29. Van Dyke T, Jacks T. (2002). Cancer modeling in the modern era: progress and challenges. Cell 108: 135-144.
30. Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK et al. (2005). BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 58: 640-644.